… efficacy of molnupiravir among mild or moderate COVID-19 … for relevant records were “Molnupiravir,”
“COVID-19,” and “… of molnupiravir with a placebo for COVID-19 treatment. The …

… This study evaluated all-cause mortality in hospitalized patients with a mild form of COVID-19
receiving molnupiravir or nirmatrelvir/ritonavir. Each group was matched in a ratio of 1:1 …

… mild-to-moderate COVID-19. In this study, we evaluate the efficacy and safety of molnupiravir
in Indian patients with mild … :1 ratio to receive molnupiravir in addition to SoC treatment (n = …

… , is being repurposed for the treatment of COVID-19. This study … molnupiravir in addition to
the standard-of-care (SOC) for the treatment of non-hospitalized patients with mild COVID-19. …

… assess the efficacy and safety of molnupiravir in patients with mild or moderate COVID-19. …
of molnupiravir in treating patients with mild-to-moderate COVID-19. Our findings reveal that …

… severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the
efficacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) …

… the effectiveness of molnupiravir in the treatment of mild to moderate COVID-19 in adult …
doctors when making decisions about how to treat adults with mild to moderate COVID-19. …

… and antiviral activity of molnupiravir dosed twice-daily for 5 days in the treatment of patients
with mild to moderate COVID-19. Hypotheses included that molnupiravir would decrease the …

… Molnupiravir is first oral antiviral drug to demonstrate a significant benefit in reducing
hospitalization or death in mild COVID-19 … Molnupiravir initially emerged as a possible treatment of …

… of treatment with molnupiravir started within 5 days after the onset of signs or symptoms
in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed Covid-19 …